信邦制药(002390.SZ)发布上半年业绩，归母净利润1.07亿元，下降6.69%

Core Viewpoint - Xinfeng Pharmaceutical (002390.SZ) reported a decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for the first half of 2025 was 2.845 billion yuan, a year-on-year decrease of 6.62% [1] - The net profit attributable to shareholders was 107 million yuan, down 6.69% compared to the previous year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was also 107 million yuan, reflecting a decrease of 7.16% year-on-year [1] - Basic earnings per share were reported at 0.0565 yuan [1]